Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15–18 Months of Age in Mexico

(2017) Flor Irene Rodriguez Melo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America

(2016) Gustavo Olivera-Botello et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru

(2016) Pio López et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment

(2016) Neil M. Ferguson et al.   SCIENCE

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

(2016) Stefan Flasche et al.   PLOS MEDICINE

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

(2016) Sophia Gailhardou et al.   PLoS Neglected Tropical Diseases

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

(2015) Bruno Guy et al.   NATURE REVIEWS MICROBIOLOGY

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers

(2015) Denis Crevat et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

(2015) Ilaria Dorigatti et al.   VACCINE

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

(2015) Bruno Guy et al.   VACCINE

Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study

(2015) Joseph Torresi et al.   VACCINE

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

(2015) Anand Prakash Dubey et al.   Human Vaccines & Immunotherapeutics

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development

(2013) Tatyana M. Timiryasova et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil

(2013) Gustavo H. Dayan et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds

(2013) Luis Á. Villar et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study

(2013) Amar-Singh HSS et al.   VACCINE

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA

(2013) Gustavo H. Dayan et al.   VACCINE

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

(2012) Arunee Sabchareon et al.   LANCET

Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru

(2012) Claudio F. Lanata et al.   VACCINE

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years

(2012) Yee Sin Leo et al.   Human Vaccines & Immunotherapeutics

Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans

(2011) Ming Qiao et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests

(2009) B. W. Johnson et al.   Clinical and Vaccine Immunology